Palvella Therapeutics Income Statement (2013-2026) | PVLA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	2.54M	2.78M	4.96M	10.99M	3.47M	0.26M		1.94M	20.05M	15.57M		0.05M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)	15.80M	18.94M	15.36M	14.07M	11.95M	13.59M		13.42M	14.33M	9.60M	-28.55M	0.98M	1.44M	3.18M	2.54M	4.07M	5.12M	6.53M	7.12M	9.33M
Selling, General & Administrative (Quarter)	4.25M	4.13M	4.08M	4.38M	4.08M	3.95M		4.02M	3.66M	6.84M	-11.45M	0.78M	1.47M	1.88M	1.82M	3.80M	4.13M	3.65M	4.18M	5.52M
Other Operating Expenses (Quarter)										14.89M	-14.89M
Operating Expenses (Quarter)	20.05M	23.07M	19.44M	18.45M	16.03M	17.54M		17.45M	17.99M	31.33M	-54.90M	1.76M	2.91M	5.06M	4.37M	7.87M	9.25M	10.18M	11.30M	14.86M
Operating Income (Quarter)	-16.76M	-19.01M	-11.00M	-7.46M	-12.33M	-12.17M		-15.51M	2.06M	-11.81M	13.39M	-1.76M	-2.91M	-5.06M	-4.37M	-7.87M	-9.25M	-10.18M	18.54M	-14.86M
EBIT (Quarter)	-16.76M	-19.01M	-11.00M	-7.46M	-12.33M	-12.17M		-15.51M	2.06M	-11.81M	13.39M	-1.76M	-2.91M	-5.06M	-4.37M	-7.87M	-9.25M	-10.18M	18.54M	-14.86M
Non-operating items
Non Operating Investment Income (Quarter)																				0.00M
Interest & Investment Income (Quarter)	0.00M	0.00M	-0.01M	-0.00M	0.13M	0.24M		0.36M	0.49M	0.55M		0.24M	0.20M	0.17M
Other Non Operating Income (Quarter)	0.46M	0.68M	0.38M	0.23M	0.68M	0.72M		-0.06M	-0.16M	0.51M	-0.29M	-0.06M	-0.27M	-0.57M	1.23M	-0.07M	0.56M			-0.03M
Non Operating Income (Quarter)	0.46M	0.68M	0.38M	0.23M	0.68M	0.72M		-0.06M	-0.16M	0.51M	0.42M		0.06M	-0.02M	0.13M	0.22M	0.56M	0.03M	-0.81M	-0.03M
Net income details
EBT (Quarter)	-16.76M	-19.01M	-11.01M	-7.46M	-12.20M	-11.93M		-15.15M	2.55M	-11.26M	13.39M	-2.54M	-4.17M	-6.78M	13.48M	-8.19M	-9.47M	-11.35M	29.07M	-15.77M
Tax Provisions (Quarter)
Profit After Tax (Quarter)	-15.50M	-16.54M	-9.54M	-5.10M	-10.30M	-9.74M		-13.20M	3.98M	-10.75M	38.65M	-2.54M	-4.17M	-6.78M	-3.95M	-8.20M	-9.47M	-11.35M	-12.71M	-15.77M
Income from Continuing Operations (Quarter)	-16.76M	-19.01M	-11.01M	-7.46M	-12.20M	-11.93M		-15.15M	2.55M	-11.26M	13.39M	-2.54M	-4.17M	-6.78M	13.48M	-8.19M	-9.47M	-11.35M	29.07M	-15.77M
Consolidated Net Income (Quarter)	-16.76M	-19.01M	-11.01M	-7.46M	-12.20M	-11.93M		-15.15M	2.55M	-11.26M	13.39M	-2.54M	-4.17M	-6.78M	13.48M	-8.19M	-9.47M	-11.35M	29.07M	-15.77M
Income towards Parent Company (Quarter)	-16.76M	-19.01M	-11.01M	-7.46M	-12.20M	-11.93M		-15.15M	2.55M	-11.26M	13.39M	-2.54M	-4.17M	-6.78M	13.48M	-8.19M	-9.47M	-11.35M	29.07M	-15.77M
Preferred Dividend Payments (Quarter)												0.19M	0.19M	0.19M	-0.58M
Net Income towards Common Stockholders (Quarter)	-16.76M	-19.01M	-11.01M	-7.46M	-12.20M	-11.93M		-15.15M	2.55M	-11.26M	13.39M	-2.73M	-4.37M	-6.97M	-3.37M	-8.19M	-9.47M	-11.35M	29.07M	-15.77M
Additional items
EPS (Basic) (Quarter)	-0.25	-0.24	-0.13	-0.07	-0.14	-0.13		-14.15	3.63	-8.70	20.52	-1.54	-2.47	-3.94	0.12	-0.74	-0.86	-1.03	-1.08	-1.20
EPS (Weighted Average and Diluted) (Quarter)	-0.25	-0.24	-0.13	-0.07	-0.14				3.62	-8.70	20.50	-1.54	-2.47	-3.94	0.12	-0.74	-0.86	-1.03	-1.08	-1.20
Shares Outstanding (Weighted Average) (Quarter)	61.91M	67.73M	64.55M	73.71M	74.12M	74.40M	74.17M	0.93M	1.09M	1.24M	1.77M	1.77M	1.77M	0.10M	2.23M	11.01M	11.05M	11.04M	11.25M	13.09M
Shares Outstanding (Diluted Average) (Quarter)	59.12M	67.73M	64.55M	73.71M	74.12M				1.10M	1.24M		1.77M	1.77M	1.77M		11.01M	11.03M	11.04M		13.09M
EBITDA (Quarter)	-15.46M	-16.15M	-9.32M	-4.98M	-10.67M	-9.84M		-13.36M	4.26M	-10.95M	37.96M	-2.73M	-4.37M	-6.97M	-3.37M	-8.19M	-9.58M	-11.13M	-12.73M	-15.76M
Interest Expenses (Quarter)													0.03M	0.22M	0.18M
Tax Rate (Quarter)

Research Tools

Palvella Therapeutics Income Statement (2013-2026) | PVLA

Create an account

Sign In

Reset Password